

RECEIVED  
CENTRAL FAX CENTER

MAY 23 2005

Law Offices of

SENNIGER POWERS

One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102Telephone (314) 231-5400  
Facsimile (314) 231-4342

## FACSIMILE TRANSMITTAL COVER SHEET

DATE: May 23, 2005 ATTORNEY DOCKET NUMBER: PHA 4142.2 (2891/3)  
PTO FACSIMILE NUMBER: (703)872-9306  
PLEASE DELIVER THIS FACSIMILE TO: Examiner Jon D. Epperson Ph.D.  
THIS FACSIMILE IS BEING SENT BY: Kathleen M. Petrillo  
NUMBER OF PAGES: 31 INCLUDING COVER SHEET  
TIME SENT: 5:39pm OPERATOR'S NAME Lori Macke

## CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Lori Macke  
Typed or printed name of person signing certification  
Lori Macke  
Signature  
May 23, 2005  
Date

Type of paper transmitted: Response to Notice of Non-Compliant Amendment and Copy of Fee Transmittal and Check from Amendment F  
Applicant's Name: Peter C. Isakson et al.  
Serial No. (Control No.): 10/038,080 Examiner: Jon D. Epperson  
Filing Date: January 3, 2002 Art Unit: 1639 Confirmation No.: 7358  
Application Title: TREATMENT OF INFLAMMATION AND INFLAMMATION-RELATED DISORDERS WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST

IF YOU DO NOT RECEIVE ALL PAGES CLEARLY, CALL BACK AS SOON AS POSSIBLE. CONFIRMING NUMBER IS (314) 231-5400.

**RECEIVED  
CENTRAL FAX CENTER**

**MAY 23 2005**

**PHA 4142.2 (2891/3)  
PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of Peter C. Isakson, et al.

Art Unit 1639

Serial No. 10/038,080

Filed January 03, 2002

Confirmation No. 7358

For TREATMENT OF INFLAMMATION AND INFLAMMATION-RELATED  
DISORDERS WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A  
LEUKOTRIENE B4 RECEPTOR ANTAGONIST

Examiner Jon D. Epperson Ph.D.

May 23, 2005

**RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT**

TO THE COMMISSIONER FOR PATENTS

SIR:

In response to the Office action dated April 22, 2005, entitled Notice of Non-Compliant Amendment, the following remarks are respectfully submitted:

**Listing of the Claims** begins on page 2 of this paper.

**Remarks** begin on page 27 of this paper.

**Conclusion** begins on page 28.